iNovacia Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

iNovacia General Information

Description

Provider of pre-clinical research services. The company is engaged in providing drug discovery services to the pharmaceutical companies for the discovery of new medicines.

Contact Information

Website
www.inovacia.se
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Kancera
Primary Office
  • Lindhagensgatan 133
  • 112 51 Stockholm
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iNovacia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore iNovacia‘s full profile, request access.

Request a free trial

iNovacia Patents

  • 15

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

iNovacia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080255153-A1 Pyrazolo[1,5- a ]-pyrimidine derivatives as human stearoyl-coa desaturase; cardiovascular, nervous system, autoimmune, metabolic and skin disorders; obesity, non-insulin-dependent diabetes; eczema, rosacea, acne, psoriasis; anticarcinogenic agents; modulation of plasma lipids Inactive 31-Aug-2007 0000000000
CA-2682016-A1 Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007 0000000000
EP-2137187-A1 Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007 0000000000
JP-2010522716-A Pyrazolo [1,5-a] pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007 0000000000
US-20080103123-A1 4-phenyl-3-substituted pyridin compounds such as tert-butyl 4-[({5-[4-(methylsulfonyl)phenyl]pyridin-2-yl}oxy)methyl]-piperidine-1-carboxylate; agonists of the g-protein-coupled receptor gpr119; antidiabetic, antiinflammatory agent, neuropathy; use with a dipeptidyl peptidase iv (dpp iv) inhibitor Inactive 21-Nov-2006 A61K31/4545
To view iNovacia’s complete patent history, request access »

iNovacia Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial